Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 20

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 20
---
 Netherlands and Germany, under the management of in-country managers supported by centralized teams in Amsterdam and London and progress to rolling out in the US leveraging the Renovaro US based staff; |

| ● | Deploy a sequencing lab in the EMEA region that will allow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization analysis and quality control; and |

| ● | Expand its team to include biomedical scientists,                                                                                         
 data scientists, machine-learning engineers, specialized medical doctors (oncologist, geneticist), high-performance-computer engineers    
 and software engineers.                                                                                                                   
 ·                                                                                                                                         
 Renovaro Cube plans to establish a state-of-the-art fully certified (CLIA and ISO standards) service laboratories to perform              
 liquid biopsies in a multi-omic approach for third parties (primarily research and academic institutes) and provide data analysis at the  
 same time. This activity serves two important goals:                                                                                      
 ·                                                                                                                                         
 It provides immediate revenues for the company providing a superior service for multi-omic sequencing servicing using Oxford Nanopore     
 Technologies for an attractive pricing and high-end services also applicable for liquid biopsies.                                         
 ·                                                                                                                                         
 The Cube needs data to expand the indications, application and improve the capabilities of the system. Acquiring this data is a lengthy   
 and expensive. We anticipate a significant number of clients will provide data sharing for a reduced price. The outcomes can be published 
 collaboratively, and the potential products will be commercialized by Renovaro Cube. The partner will receive royalties.                  
 ·                                                                                                                                         
 A first service laboratory will be established in the Netherlands and rapidly expanded to other sites in the EU, US                       
 and rest of the world.                                                                                                                    |

<div align='center'>14</div>

Our Intellectual Property

Patents and licenses are key to
our business. Our strategy is to file patent applications to protect technology, inventions, and improvements to inventions that we consider
important for the development of our business. We rely on a combination of patent, copyright, trademark, and trade secret laws, as well
as continuing technological innovations, proprietary knowledge, and various third-party agreements, including, without limitation, confidentiality
agreements, materials transfer agreements, research agreements, and licensing agreements, to establish and protect our proprietary rights.
We aim to take advantage of all of the intellectual property rights that are available to us and seek the protection of those rights so
that we can fully exploit our innovations.

We also protect our proprietary information by requiring our employees, consultants,
contractors